HIGHLIGHTS
- who: Jiahui He and Qinyong Hu from the Medical University of Warsaw, Poland have published the research: Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer, in the Journal: (JOURNAL) of October/28,/2027
- what: The results of this study showed that the ORR was 33%, the median OS was 7.7 months, the PFS was 1.9 months, and the 1-year survival rate was 37.7%.
- how: These results showed that there was no significant improvement in the primary endpoint of OS compared with chemotherapy alone . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.